Ann: CHM CDH17 Phase 1/2 clinical trial approved for initiation, page-10

This is Hashan De Silva, runs KP Rx Healthcare Opportunities Fund. They haven't been around long but bought NEU at $1 and sold at $20.

Talks about how this is the best time ever to buy into the biotech market. He mentions companies who listed back in 2021 have been decimated by capital markets, some companies down 90% from their IPO struggling to now raise capital. Sound familiar? Listen to the very end of the video, "one company in particular we think we'll be able to enter at a $20million evaluation that is 3 years and a phase 2b trial away from a multi billion dollar exit". I wonder if that could be Chimeric and CHM 2101?